Clinical Trials

Breast Neoplasms

NCT03786094 2023-11-01

FORTRESS

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

NCT01463891 2023-07-24

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

963 enrolled

Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

123 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01126736 2023-06-22

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

98 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

52 enrolled 9 charts

Breast Neoplasms

NCT01327885 2023-06-22

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

452 enrolled 11 charts

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT03613181 2023-04-24

ANGLeD

Phase 3 Unknown

150 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

23 enrolled 14 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT03027245 2022-07-13

IRENE

353 enrolled

Breast Neoplasms, Peripheral Nervous System Diseases

NCT03245450 2022-06-28

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

40 enrolled 30 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT02574455 2022-06-15

ASCENT

529 enrolled 23 charts 1 FDA

Breast Neoplasms

NCT02513472 2022-05-05

ENHANCE-1

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01126749 2022-02-28

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Phase 1/2 Terminated

92 enrolled 15 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

76 enrolled 24 charts

Breast Neoplasms

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms

NCT00337103 2020-06-18

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

1,276 enrolled 22 charts

Breast Neoplasms

NCT03058406 2020-04-06

HAL03T

256 enrolled

NCT00388726 2020-01-07

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

762 enrolled 12 charts

Breast Neoplasms

NCT03583944 2019-11-27

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Phase 4 Completed

200 enrolled

Breast Neoplasms

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT01945710 2019-07-23

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Phase 1 Completed

62 enrolled 28 charts

Tumor-Agnostic

Neoplasms

NCT02723877 2019-03-22

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

41 enrolled

Breast Neoplasms

NCT03437083 2019-01-25

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

340 enrolled